Document Detail


Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
MedLine Citation:
PMID:  20699617     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tacrolimus (TAC) is an immunosuppressant drug discovered in 1984 by Fujisawa Pharmaceutical Co., Ltd. This drug belongs to the group of calcineurin inhibitors, which has been proven highly effective in preventing acute rejection after transplantation of solid organs. However, neurotoxicity and nephrotoxicity are its major adverse effects. Posterior reversible encephalopathy syndrome (PRES) is the most severe and dramatic consequence of calcineurin inhibitor neurotoxicity. It was initially described by Hinchey et al. in 1996 [N Engl J Med 1996;334:494-450]. Patients typically present with altered mental status, headache, focal neurological deficits, visual disturbances, and seizures. Magnetic resonance imaging is the most sensitive imaging test to detect this. With the more deep-going studies done recently, we have learnt more about this entity. It was noted that this syndrome is frequently reversible, rarely limited to the posterior regions of the brain, and often located in gray matter and cortex as well as in white matter. Therefore, in this review, the focus is on the current understanding of clinical recognition, pathogenesis, neuroimaging and management of TAC-associated PRES after solid organ transplantation.
Authors:
Qisi Wu; Christian Marescaux; Valérie Wolff; Mi-Young Jeung; Romain Kessler; Valérie Lauer; Yangmei Chen
Related Documents :
15919467 - Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrol...
20883287 - Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
15050147 - Immunosuppression following intestinal transplantation.
21047207 - Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.
8477197 - Serum erythropoietin and circulating bfu-e in patients with multiple myeloma and anaemi...
24598067 - Development of a new allogeneic hematopoietic stem cell transplantation method with co-...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-08-12
Journal Detail:
Title:  European neurology     Volume:  64     ISSN:  1421-9913     ISO Abbreviation:  Eur. Neurol.     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-03     Completed Date:  2010-12-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0150760     Medline TA:  Eur Neurol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  169-77     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 S. Karger AG, Basel.
Affiliation:
The Second Affiliated Hospital , Chongqing Medical University, Chongqing, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Immunosuppressive Agents / adverse effects*
Magnetic Resonance Imaging / methods
Neurotoxicity Syndromes / diagnosis,  etiology*,  therapy
Organ Transplantation / methods
Tacrolimus / adverse effects*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Injury of the spino-thalamo-cortical pathway is necessary for central post-stroke pain.
Next Document:  Definitions of types of hearing impairment: a discussion paper.